陕西盘龙药业集团股份有限公司 关于注销部分募集资金账户的公告

Fundraising Overview - The company issued 9,352,740 shares of common stock at a price of RMB 32.29 per share, raising a total of RMB 301,999,974.60 [1] - After deducting underwriting fees and other related expenses, the net amount raised was RMB 294,836,292.23 [1] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure efficient use of funds and protect investor rights [2] - A tripartite supervision agreement was signed with the sponsor and banks to manage the raised funds [2] Fund Account Closure - The account used for the "Traditional Chinese Medicine Formula Granule R&D and Industrialization Project" was closed on February 4, 2026, after the funds were permanently transferred to working capital, leaving a balance of RMB 0.00 [2]